"We are delighted that Dr. Smyth has decided to join our Board of Directors," said Robert Savage, Chairman of the Board of Directors. "It is a tremendous opportunity to be able to bring someone with his wealth of expertise and experience in the field of oncology to the EpiCept Board, particularly as the company prepares for the launch in Europe of Ceplene (histamine dihydrochloride) with a commercial partner. Dr. Smyth will also be an invaluable asset to EpiCept as it pursues regulatory approval for Ceplene in other key global markets and advances its promising earlier-stage oncology compound crinobulin."
Recent Developments On April 13, 2009, EPCT announced the appointment of A. Collier Smyth, M.D., former senior vice president of medical strategy-oncology at Bristol- Myers Squibb Company (BMS), to its Board of Directors. Prior to his recent retirement from BMS, Dr. Smyth led oncology medical affairs in the United States, including the U. S. life-cycle development of paclitaxel (Taxol), carboplatin (Paraplatin) and ifosfamide (Ifex). Most recently, he participated in the launch of multiple BMS oncology drugs, including cetuximab (Erbitux), dasatinib (Sprycel) and ixabepilone (Ixempra).